Guggenheim keeps this U.S. biotech stock as its top pick
Investing.com -- Guggenheim has identified its top pick in the biotechnology sector, highlighting a company developing treatments for diabetic macular edema that could address shortfalls in existing therapies.
Investing.com -- Guggenheim has identified its top pick in the biotechnology sector, highlighting a company developing treatments for diabetic macular edema that could address shortfalls in existing therapies.
What's Your Reaction?
